APEN

Apollo Endosurgery, Inc. [APEN] Stock Forecast

Buy or Sell ? Support and Resistance

What is MACD and how to read it?

How RSI can help?
RSI : 000

APEN Stock Summary

In the News

12:00 04 Mar 2024 APEN

Buy-rated Boston Scientific's $615 million takeover of Apollo Endosurgery is a positive, says Needham

Boston Scientific Corp.'s BSX, +0.88% $615 million acquisition of Apollo Endosurgery Inc. APEN, +65.50% announced earlier is complementary to the former's endoscopy franchise, as it leverages its gastroenterologist call point while offering the potential for it to expand into surgical endoscopy and bariatric surgery, Needham analysts aid Tuesday. The deal is expected to have no material impact on Boston Scientific's 2023 per-share earnings but to boost it after that.

10:50 04 Mar 2024 APEN

Apollo Endosurgery Stock Soars on Buyout Buzz

Apollo Endosurgery Inc (NASDAQ:APEN) stock is soaring, up 63.4% at $9.80 at last glance, after news that Boston Scientific Corp (BSX) will acquire the medical equipment name for $417 million.

07:13 04 Mar 2024 APEN

Boston Scientific to acquire Apollo Endosurgery for $615 million in cash

Boston Scientific Corp. BSX, -0.82% said Tuesday it has agreed to acquire Apollo Endosurgery Inc. APEN, for $10 a share, or about $615 million in cash. The news sent Apollo's stock, which closed Monday at $6, up 61% in premarket trade.

10:18 04 Mar 2024 APEN

Apollo Endosurgery, Inc. (APEN) Q3 2022 Earnings Call Transcript

Apollo Endosurgery, Inc. (NASDAQ:APEN ) Q3 2022 Earnings Conference Call November 1, 2022 4:30 PM ET Company Participants Matt Kreps – Investor Relations Chas McKhann – Chief Executive Officer Jeff Black – Chief Financial Officer Conference Call Participants Mathew Blackman – Stifel Matt Hewitt – Craig-Hallum Capital Frank Takkinen – Lake Street Capital Josh Jennings – Cowen Simran Kaur – Piper Sandler Operator Good afternoon, ladies and gentlemen. And welcome to the Apollo Endosurgery Third Quarter 2022 Results Call.

08:00 04 Mar 2024 APEN

Apollo Endosurgery to Report Third Quarter Results on November 1, 2022

AUSTIN, TX / ACCESSWIRE / October 18, 2022 / Apollo Endosurgery, Inc. ("Company" or "Apollo") (NASDAQ:APEN), a global leader in next-generation minimally invasive medical devices for gastrointestinal and bariatric procedures, today announced that the Company is scheduled to release financial results for the third quarter ended September 30, 2022 on Tuesday, November 1, 2022, after market close. In conjunction with the release, Apollo will host a live webcast audio call with presentation slides at 3:30 p.m.

02:37 04 Mar 2024 APEN

Apollo Endosurgery, Inc. (APEN) CEO Chas McKhann on Q2 2022 Results - Earnings Call Transcript

Apollo Endosurgery, Inc. (NASDAQ:APEN ) Q2 2022 Earnings Conference Call August 2, 2022 4:30 PM ET Company Participants Matt Kreps - Investor Relations Chas McKhann - Chief Executive Officer Jeff Black - Chief Financial Officer Conference Call Participants Chris Cooley - Stephens Simran Kaur - Piper Sandler Frank Takkinen - Lake Street Capital Matt Hewitt - Craig-Hallum Capital Operator Good afternoon, ladies and gentlemen and welcome to Apollo Endosurgery Second Quarter 2022 Results. At this time all participants have been placed on a listen-only mode and we will open the floor for your questions and comments after the presentation.

04:45 04 Mar 2024 APEN

Apollo Endosurgery: Collect Shares At A Discount Following Q2 Earnings

Apollo Endosurgery came in with another strong quarter of top-line growth whilst growing gross margins on the same. The company saw substantial growth in each of its key segments, coupled with regulatory momentum in its Apollo ESG and REVISE series.

08:00 04 Mar 2024 APEN

Apollo Endosurgery to Report Second Quarter Results on August 2, 2022

AUSTIN, TX / ACCESSWIRE / July 21, 2022 / Apollo Endosurgery, Inc. ("Company" or "Apollo") (NASDAQ:APEN), a global leader in next-generation minimally invasive medical devices for gastrointestinal and bariatric procedures, today announced that the Company is scheduled to release financial results for the second quarter ended June 30, 2022 on Tuesday, August 2, 2022, after market close. In conjunction with the release, Apollo will host a live webcast audio call with presentation slides at 3:30 p.m.

04:15 04 Mar 2024 APEN

Hot Penny Stocks to Watch Right Now? 3 For Your July List

Which penny stocks are you watching right now? The post Hot Penny Stocks to Watch Right Now?

10:31 04 Mar 2024 APEN

Apollo Endosurgery's New Obesity Endoscopic Systems Receive FDA Nod

Apollo Endosurgery Inc (NASDAQ: APEN) announced the marketing authorization of the Apollo ESG, Apollo ESG Sx, Apollo REVISE, and Apollo REVISE Sx Systems through the FDA De Novo Classification process. The process is a premarket review pathway for low-to moderate-risk devices.

APEN Financial details

Company Rating
Neutral
Market Cap
579.72M
Income
-39.84M
Revenue
76.86M
Book val./share
1.08
Cash/share
1.88
Dividend
-
Dividend %
-
Employees
202
Optionable
No
Shortable
Yes
Earnings
31 Jul 2023
P/E
-7.59
Forward P/E
-
PEG
-2.49
P/S
7.54
P/B
9.28
P/C
-
P/FCF
-17.05
Quick Ratio
1.82
Current Ratio
2.35
Debt / Equity
1.75
LT Debt / Equity
1.13
-
-
EPS (TTM)
-1.07
EPS next Y
-
EPS next Q
-
EPS this Y
19.51%
EPS next Y
-
EPS next 5Y
-
EPS last 5Y
-15.76%
Revenue last 5Y
4.78%
Revenue Q/Q
8.89%
EPS Q/Q
14.29%
-
-
-
-
SMA20
-
SMA50
-
SMA100
-
Inst Own
146.08%
Inst Trans
1.2%
ROA
-36%
ROE
-89%
ROC
-0.39%
Gross Margin
55%
Oper. Margin
-36%
Profit Margin
-52%
Payout
-
Shs Outstand
57.97M
Shs Float
39.54M
-
-
-
-
Target Price
9.5
52W Range
3.49-10.3
52W High
-
52W Low
-
RSI
-
Rel Volume
1.23
Avg Volume
1.33M
Volume
-
Perf Week
-
Perf Month
-
Perf Quarter
-
Perf Half Y
-
-
-
-
-
Beta
2.32304
-
-
Volatility
0%, 0%
Prev Close
-
Price
-
Change
-

APEN Financial Performance

Yearly Fundamentals Overview

Last date of statement is 2022-12-31

Metric History 2018-12-312019-12-312020-12-312021-12-31 2022-12-31
2.02K2.02K2.02K2.02K2.02K
Revenue per share
3.082.351.852.081.89
Net income per share
-2.31-1.27-0.99-0.82-0.98
Operating cash flow per share
-1.17-1.19-0.91-0.48-0.77
Free cash flow per share
-1.31-1.23-0.94-0.53-0.84
Cash per share
1.211.391.5931.4
Book value per share
1.460.10.32.020.8
Tangible book value per share
0.69-0.51-0.21.70.59
Share holders equity per share
1.460.10.32.020.8
Interest debt per share
1.282.692.772.051.52
Market cap
68.28M61.4M77.37M254.95M405.28M
Enterprise value
65.47M85.43M99.03M217.83M405.34M
P/E ratio
-1.49-2.24-3.42-10.33-10.17
Price to sales ratio
1.121.211.844.055.27
POCF ratio
-2.95-2.4-3.72-17.64-12.96
PFCF ratio
-2.63-2.31-3.61-16.02-11.92
P/B Ratio
2.3728.9211.464.1612.43
PTB ratio
2.3728.9211.464.1612.43
EV to sales
1.081.682.363.465.27
Enterprise value over EBITDA
-2.03-3.21-7.34-12.68-14.47
EV to operating cash flow
-2.83-3.33-4.76-15.07-12.97
EV to free cash flow
-2.52-3.21-4.62-13.69-11.92
Earnings yield
-0.67-0.45-0.29-0.1-0.1
Free cash flow yield
-0.38-0.43-0.28-0.06-0.08
Debt to equity
0.7325.418.580.871.75
Debt to assets
0.280.720.750.410.52
Net debt to EBITDA
0.09-0.9-1.612.160
Current ratio
1.970.975.027.922.35
Interest coverage
-9.87-7.19-3.01-2.31-5.96
Income quality
0.50.930.920.590.78
Dividend Yield
00000
Payout ratio
00000
Sales general and administrative to revenue
0.220.270.260.290.27
Research and developement to revenue
0.20.20.180.150.15
Intangibles to total assets
0.20.180.150.070.08
Capex to operating cash flow
0.120.040.030.10.09
Capex to revenue
-0.05-0.02-0.01-0.02-0.04
Capex to depreciation
-0.31-0.24-0.17-0.45-0.93
Stock based compensation to revenue
0.020.030.050.10.09
Graham number
8.711.682.586.14.2
ROIC
-0.8-0.52-0.24-0.17-0.3
Return on tangible assets
-0.77-0.45-0.34-0.2-0.39
Graham Net
-0.41-1.45-1.021.12-0.01
Working capital
23.67M-1.79M46.86M100.21M53.34M
Tangible asset value
13.68M-11M-4.56M51.55M24.18M
Net current asset value
2.48M-21.46M-12.16M44.41M15.24M
Invested capital
0.7325.418.580.871.75
Average receivables
11.56M10.31M8.73M9.15M12.53M
Average payables
16.81M12.6M6.79M4.13M6M
Average inventory
12.14M9.4M9.59M11.14M15.11M
Days sales outstanding
68.3266.4571.3458.471.19
Days payables outstanding
201.79144.3567.7359.6978.65
Days of inventory on hand
131.06129.23189.93155.82193.44
Receivables turnover
5.345.495.126.255.13
Payables turnover
1.812.535.396.114.64
Inventory turnover
2.782.821.922.341.89
ROE
-1.59-12.92-3.35-0.4-1.22
Capex per share
-0.15-0.05-0.03-0.05-0.07

Quarterly Fundamentals Overview

Last date of statement is 2022-12-31 for Q4

Metric History 2021-12-312022-03-312022-06-302022-09-30 2022-12-31
2.02K2.02K2.02K2.02K2.02K
Revenue per share
0.420.420.480.480.7
Net income per share
-0.27-0.21-0.26-0.28-0.32
Operating cash flow per share
-0.11-0.22-0.15-0.15-0.34
Free cash flow per share
-0.13-0.23-0.16-0.18-0.36
Cash per share
2.372.061.851.641.88
Book value per share
1.61.391.191.041.08
Tangible book value per share
1.351.150.970.820.8
Share holders equity per share
1.61.391.191.041.08
Interest debt per share
1.511.391.361.351.92
Market cap
322.52M239.9M147.31M225.07M301.53M
Enterprise value
285.4M211.9M126.39M212.26M301.59M
P/E ratio
-7.75-7.13-3.53-4.92-7.89
Price to sales ratio
19.9414.47.6311.514.15
POCF ratio
-74.33-27.61-24.25-36.33-29.27
PFCF ratio
-66.72-25.96-22.22-30.74-27.88
P/B Ratio
5.274.363.065.329.25
PTB ratio
5.274.363.065.329.25
EV to sales
17.6512.726.5510.8414.15
Enterprise value over EBITDA
-52.55-33.83-14.99-22.7-39.84
EV to operating cash flow
-65.78-24.39-20.81-34.26-29.27
EV to free cash flow
-59.04-22.93-19.06-28.99-27.89
Earnings yield
-0.03-0.04-0.07-0.05-0.03
Free cash flow yield
-0.01-0.04-0.05-0.03-0.04
Debt to equity
0.870.981.121.281.75
Debt to assets
0.410.430.450.470.52
Net debt to EBITDA
6.834.472.481.37-0.01
Current ratio
7.927.786.3762.35
Interest coverage
-1.44-5.93-5.45-5.45-7.08
Income quality
0.421.030.580.541.08
Dividend Yield
00000
Payout ratio
00000
Sales general and administrative to revenue
0.280.310.260.270.24
Research and developement to revenue
0.150.160.150.140.16
Intangibles to total assets
0.070.070.070.070.08
Capex to operating cash flow
0.110.060.090.180.05
Capex to revenue
-0.03-0.03-0.03-0.06-0.02
Capex to depreciation
-0.66-0.74-0.75-1.46-0.71
Stock based compensation to revenue
0.10.090.090.10.08
Graham number
3.132.572.632.562.77
ROIC
-0.05-0.07-0.06-0.07-0.08
Return on tangible assets
-0.09-0.07-0.09-0.11-0.09
Graham Net
0.890.670.470.27-0.01
Working capital
100.21M94.55M88.04M82.3M53.34M
Tangible asset value
51.55M45.72M39.16M33.66M24.18M
Net current asset value
44.41M38.52M31.82M25.06M15.24M
Invested capital
0.870.981.121.281.75
Average receivables
10.18M10.57M11.79M12.71M13.95M
Average payables
4.55M5.49M6.79M6.97M7.1M
Average inventory
11.64M12.61M13.99M15.71M17.47M
Days sales outstanding
56.0959.7758.3659.3163.3
Days payables outstanding
58.3678.9777.3868.9767.06
Days of inventory on hand
152.35163.62158.83170.08164.92
Receivables turnover
1.61.511.541.521.42
Payables turnover
1.541.141.161.31.34
Inventory turnover
0.590.550.570.530.55
ROE
-0.17-0.15-0.22-0.27-0.29
Capex per share
-0.01-0.01-0.01-0.03-0.02

APEN Frequently Asked Questions

What is Apollo Endosurgery, Inc. stock symbol ?

Apollo Endosurgery, Inc. is a US stock , located in Austin of Tx and trading under the symbol APEN

Is Apollo Endosurgery, Inc. buy or a sell ?

2 stock analysts have 2 predictions with a medium analyst target price of $9.5. The lowest prediction is $9 and the highest is $10

What is APEN stock prediction ?

What is Apollo Endosurgery, Inc. stock quote today ?

Apollo Endosurgery, Inc. stock price is $- today.

Is Apollo Endosurgery, Inc. stock public?

Yes, Apollo Endosurgery, Inc. is a publicly traded company.

Something similar

Top by Market Cap
Check Those
Similar Market Cap